BioXcel to Host Event on IGALMI Launch Strategy, 86M Addressable Episodes

BioXcel Therapeutics announced it will host a virtual event on April 23 to discuss the launch strategy for IGALMI, its treatment for acute agitation. The event will focus on commercial plans ahead of the November 14 PDUFA target action date. A recent market assessment identified up to 86 million addressable annual episodes of acute agitation in the at-home setting in the U.S., highlighting a significant market opportunity.